BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 7, Pages 998
Publisher
MDPI AG
Online
2019-07-17
DOI
10.3390/cancers11070998
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer
- (2019) Yuxuan Wang et al. JAMA Oncology
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
- (2018) J B Bachet et al. ANNALS OF ONCOLOGY
- Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients
- (2018) Nele Boeckx et al. Clinical Colorectal Cancer
- RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014
- (2018) Astrid Lièvre et al. DIGESTIVE AND LIVER DISEASE
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- 542PDroplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer
- (2018) E Van Cutsem et al. ANNALS OF ONCOLOGY
- 607TiPBIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703)
- (2018) D Kotani et al. ANNALS OF ONCOLOGY
- Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
- (2017) Jeremy C. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- 535PENCORAFENIB (LGX818), AN ORAL BRAF INHIBITOR, IN PATIENTS (PTS) WITH BRAF V600E METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF DOSE EXPANSION IN AN OPEN-LABEL, PHASE 1 STUDY
- (2017) C.A. Gomez-Roca et al. ANNALS OF ONCOLOGY
- Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)
- (2016) R.B. Corcoran et al. ANNALS OF ONCOLOGY
- Investigating the poor outcomes of BRAF -mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials
- (2016) J.F. Seligmann et al. ANNALS OF ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA
- (2016) Nicolas Pécuchet et al. CLINICAL CHEMISTRY
- A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker
- (2016) S. Garrigou et al. CLINICAL CHEMISTRY
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
- (2016) D. S. Hong et al. Cancer Discovery
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
- (2014) P. Laurent-Puig et al. CLINICAL CANCER RESEARCH
- Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
- (2014) Jean-Yves Douillard et al. Journal of Thoracic Oncology
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
- (2011) Cecily P. Vaughn et al. GENES CHROMOSOMES & CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now